MGC

STEALTHGAS INC. Reports Fourth Quarter and Twelve Months 2023 Financial and Operating Results

Retrieved on: 
Wednesday, February 21, 2024
Cerberus, Conference call, Depreciation, PIN, Share repurchase, Growth, Sale, CBM, Net income, Conference, GAAP, JV, Dry dock, Lucidity, MGC, Webcast, Interest, EPS, LPG, Cryptocurrency

Drydocking costs for the three months ended December 31, 2023 and 2022 were $0.03 million and $0.6 million, respectively.

Key Points: 
  • Drydocking costs for the three months ended December 31, 2023 and 2022 were $0.03 million and $0.6 million, respectively.
  • No vessels were drydocked during the fourth quarter of 2023 while drydocking expenses during the fourth quarter of 2022 mainly relate to the drydocking of two vessels.
  • Management fees for the three months ended December 31, 2023 and 2022 were $1.0 million and $1.3 million, respectively.
  • General and administrative expenses for the three months ended December 31, 2023 and 2022 were $1.7 million and $0.8 million, respectively.

AM Best Affirms Credit Ratings of Mercury General Corporation and Its Subsidiaries

Retrieved on: 
Thursday, February 15, 2024
Banking, Professional Services, Insurance, Finance, Mercury General, FSR, Risk management, AM Best, PPA, MCY, MGC, Mercury, Good, Credit, Environment

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” (Excellent) for the members of Mercury Casualty Group (Mercury).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” (Excellent) for the members of Mercury Casualty Group (Mercury).
  • Concurrently, AM Best has affirmed the Long-Term ICR of “bbb” (Good) of the organization’s publicly traded ultimate parent, Mercury General Corporation (MGC) (Los Angeles, CA) [NYSE: MCY].
  • AM Best also has affirmed the Long-Term Issue Credit Rating of “bbb” (Good) of MGC’s $375 million, 4.4% senior unsecured notes, due 2027.
  • The outlook of these Credit Ratings (ratings) is stable.

BETR ANNOUNCES 2024 ONLINE SPORTS BETTING AND IGAMING EXPANSION PLANS

Retrieved on: 
Tuesday, January 23, 2024
JV, Social media, Partnership, DBA, Sport, Economics, Sportsbook, Marketing, The Cordish Companies, NFL, MGC, Fantasy sport

MIAMI, Jan. 23, 2024 /PRNewswire/ -- Betr Holdings, Inc. (Betr), the Miami-based sports gaming and sports media company, today announced new market access deals for online sportsbook and casino in Pennsylvania and for online sportsbook in Colorado and Kentucky. The company has already secured market access in Indiana, has applied for a sports wagering license in Maryland, and is currently live in Ohio, Virginia, and Massachusetts with its beta product. Betr remains on track to launch V1 of its Sportsbook ahead of the 2024 NFL season. The announcement comes on the heels of a highly successful 2023 for Betr, where the company launched its real money fantasy sports product, Betr Picks, ahead of the 2023 NFL season. Betr quickly achieved significant scale via Betr Picks – both with respect to paying users and revenue – and has been able to do so efficiently and profitably as the company has quickly become a leader in real money Fantasy Sports.

Key Points: 
  • Pennsylvania will also be the first state where Betr will launch Betr Casino (pending regulatory approval), its regulated iGaming vertical.
  • In Colorado, Betr has secured online sportsbook market access with Boulter Developments, pending licensing approval from the Colorado Division of Gaming.
  • We plan on replicating this playbook for Betr Sportsbook and Betr Casino after releasing V1 of our Sportsbook later this year.
  • By the end of 2024, we should see a further step change in our scale, while also having successfully laid the foundations of at least four distinct business units: Betr Fantasy, Betr Sportsbook, Betr Casino, and Betr Media."

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Stomach, INN, Risk, HER2, Breast, Tissue, Heart, Cancer, Neoplasm, Cardiotoxicity, Infection, Anatomy, Paclitaxel, IIA, Breast cancer, ATC, European, Allergy, Metastasis, Blood, Capecitabine, MBC, EBC, Safety, Heart failure, MGC, Patient, Medical Subject Headings, Agency, European Commission, Cyclophosphamide, Immune system, Docetaxel, Carboplatin, International, Language, Cisplatin, Select, Enzyme inhibitor, Medicine, FISH, Radiation, Lymph, Arm, European Medicines Agency, Fluorouracil, Doxorubicin, Medical device

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

SIGTRAN Protocol Testing and Emulation Suite

Retrieved on: 
Thursday, December 14, 2023
Transfer, MAP, TCAP, GMSC, TDM, Network switching subsystem, M3UA, RNC, Service, SCCP, ICMP, SMSC, BICC, GGSN, UMTS, Mobile Application Part, ISDN, MTP, MNC, SSF, TUP, ISUP, Human, SGSN, IP, GPRS, SIGTRAN, MGC, SS7, GMLC, Software-defined networking, SCTP, GUI, IUA, IMSI, CAP, EIR, INAP, TMSI, MCC, SCF, MSC, SUA, Internet, HLR, CCBS, ITU, Bearer, PRI, ANSI, Analyser, GSM, MSIN

From small-scale deployments to large and complex networks, our SIGTRAN Protocol Test Solutions scales seamlessly, offering consistent performance across varied scenarios.

Key Points: 
  • From small-scale deployments to large and complex networks, our SIGTRAN Protocol Test Solutions scales seamlessly, offering consistent performance across varied scenarios.
  • It supports the same application and call management functions as SS7 but uses two protocol layers on top of Internet Protocol (IP): Stream Control Transport Protocol (SCTP) and M3UA MTP3 User Adaptation Layer.
  • GL's SIGTRAN Protocol Test Suite includes:
    GL's multi-protocol emulation test suite Message Automation and Protocol Simulation (MAPS™) SIGTRAN is an advanced protocol emulator designed for emulating SS7 over IP Networks.
  • NetSurveyorWeb™ is a web-based dashboard with back-end database that connects to a SIGTRAN protocol analyzer probe, enabling the monitoring of the entire SIGTRAN network.

2024 Most Valuable Player (MVP) Award Finalists & Honorable Mentions Announced

Retrieved on: 
Tuesday, December 19, 2023
Most valuable player, NRCA, MVP, CAE, MGC

ROSEMONT, Ill., Dec. 19, 2023 /PRNewswire-PRWeb/ -- The Roofing Alliance proudly announces the 2023-24 Most Valuable Player (MVP) Awards finalists and honorable mention recipients. The winners for Outstanding Performance and Leadership, Outstanding Community Involvement and the recipient of Professional Roofing's Best of the Best, a recognition co-sponsored by OMG Roofing Products and Professional Roofing magazine, will be announced during the NRCA's Awards Ceremony on Feb. 7, 2024, at the International Roofing Expo in Las Vegas, Nevada.

Key Points: 
  • ROSEMONT, Ill., Dec. 19, 2023 /PRNewswire-PRWeb/ -- The Roofing Alliance proudly announces the 2023-24 Most Valuable Player (MVP) Awards finalists and honorable mention recipients.
  • Through the MVP Award program, the Roofing Alliance honors leadership in the field.
  • Since the program's inception more than 20 years ago, 764 employees have been nominated and 285 winners and finalists have been recognized.
  • For more information about the Roofing Alliance or the Most Valuable Player Awards, please contact Alison L. LaValley, CAE at [email protected] or visit roofingalliance.net.

Mink Ventures Commences Option for Warren Copper Nickel Project, Timmins, Ontario

Retrieved on: 
Wednesday, July 5, 2023
Exercise, OGS, Magnetism, USS Mink (IX-123), Mink, Technical report, KGC, AG, IP, Whitesides, Acquisition, Copper, Nature, National instrument, Map, Indian stock exchange, National Instrument 43-101, Mining, GIS, Rare-earth element, Uranium mining, MGC, Timmins

TORONTO, ON, July 6, 2023 - (ACN Newswire) - Mink Ventures Corporation (TSXV: MINK) ("MINK" or the "Company") announces that it has issued 250,000 common shares of the Company (the "Common Shares") and 250,000 warrants to purchase Mink common shares (the "Warrants") to commence its previously announced option of the Warren Copper-Nickel Project (the "Warren Project").

Key Points: 
  • TORONTO, ON, July 6, 2023 - (ACN Newswire) - Mink Ventures Corporation (TSXV: MINK) ("MINK" or the "Company") announces that it has issued 250,000 common shares of the Company (the "Common Shares") and 250,000 warrants to purchase Mink common shares (the "Warrants") to commence its previously announced option of the Warren Copper-Nickel Project (the "Warren Project").
  • To commence the option, MINK issued to US Copper Corp. 250,000 MINK common shares and 250,000 MINK three-year common share purchase warrants exercisable at a price of $0.25.
  • To maintain and ultimately exercise the option MINK must incur $300,000 in exploration expenditures and issue an additional 750,000 MINK common shares within 21 months.
  • - The Warren Project complements Mink's key Montcalm project due to the distinctly similar, prospective geological environments as well as the presence of significant Cu Ni zones at Warren.

Historic Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register

Retrieved on: 
Wednesday, May 31, 2023
Epilepsy, GMC, LSE, General Medical Council, MXC, IMP, ZAM, ASX, Research, MGC, Hemispherectomy, Parkinson's disease, Patient, OTC, United Kingdom, NHS, Chronic pain, Pharmaceutical industry

LONDON, May 31, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.

Key Points: 
  • It is part of MGC's rigorous clinical development programme for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy.
  • The initiative permits clinicians listed on The General Medical Council (GMC) specialist register to prescribe CannEpil®.
  • The delivery also supports the RESCAS study, a research initiative aiming to address the substantial unmet medical need of refractory epilepsy.
  • CannEpil® was supplied to the 'I AM Billy Foundation' through the NHS's Refractory Epilepsy Specialist Clinical Advisory Service, the only route in the UK for patients to receive public funding for cannabis-based treatments of refractory epilepsy.

Chris-Craft Names Millennium Group Corporation (Asia) Exclusive Dealer, Expands Distribution in ASEAN Region

Retrieved on: 
Friday, May 5, 2023
Partnership, PLC, ASEAN, Launch, Chris Craft, Marine, Winnebago Industries, Growth, MGC, NYSE, Nightclub, Calypso

SARASOTA, Fla. and BANGKOK, Thailand, May 05, 2023 (GLOBE NEWSWIRE) -- Chris-Craft, America’s Boatbuilder Since 1874 and wholly owned subsidiary of Winnebago Industries (NYSE: WGO), has named Millennium Group Corporation (Asia) PLC (MGC-Asia) its exclusive authorized retailer for Chris-Craft boats in Thailand and the ASEAN region.

Key Points: 
  • SARASOTA, Fla. and BANGKOK, Thailand, May 05, 2023 (GLOBE NEWSWIRE) -- Chris-Craft, America’s Boatbuilder Since 1874 and wholly owned subsidiary of Winnebago Industries (NYSE: WGO), has named Millennium Group Corporation (Asia) PLC (MGC-Asia) its exclusive authorized retailer for Chris-Craft boats in Thailand and the ASEAN region.
  • MGC-Asia is a leading automotive and marine retailer that has earned an excellent reputation selling and servicing luxury goods for over two decades.
  • “MGC Marine's expertise in the luxury segment will now help Chris-Craft expand in a fast-growing market for recreational marine activities.
  • We believe our quality boats combined with MGC-Asia’s Lifestyle Mobility Ecosystem will elevate Chris-Craft into a leading brand in Thailand and ASEAN."

ArtemiC TM Listed as an OTC Drug in the USA; AMC Places US$2m Order

Retrieved on: 
Wednesday, March 22, 2023
LSE, Partnership, Database, MXC, COVID-19, Big Pharma, ASX, MGC, AMC, NDC, Clinical trial, Patient, OTC, PBM, FDA, Safety, Inflammation, Pharmaceutical industry

LONDON, March 22, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be available in US Pharmacy Benefit Management (PBM) networks starting April 2023, with ongoing discussions for its inclusion in other independent outlets.

Key Points: 
  • (AMC), ArtemiC™ will be available in US Pharmacy Benefit Management (PBM) networks starting April 2023, with ongoing discussions for its inclusion in other independent outlets.
  • In response to the NDC listing, AMC has placed a US$2 million purchase order for ArtemiC™, with production set to commence immediately.
  • ArtemiC™, which completed a successful Phase II Clinical Trial in 2020, has demonstrated significant benefits for patients suffering from moderate COVID-19.
  • The versatile treatment has shown a full safety and efficacy profile with no drug-adverse events and can be used in community settings and hospitals alike.